GlobeNewswire: MediciNova, Inc. Contains the last 10 of 416 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T01:04:59ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/26/2852845/0/en/MediciNova-Receives-a-Notice-of-Allowance-for-a-New-Patent-Covering-MN-166-ibudilast-for-the-Treatment-of-Macular-Injury-in-Japan.html?f=22&fvtc=4&fvtv=5976MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan2024-03-26T23:00:00Z<![CDATA[LA JOLLA, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has received a Notice of Allowance from the Japan Patent Office for a pending patent application which covers MN-166 (ibudilast) for the treatment of macular injury associated with progressive multiple sclerosis.]]>https://www.globenewswire.com/news-release/2024/03/20/2849862/0/en/MediciNova-Announces-Two-Abstracts-regarding-MN-001-tipelukast-and-MN-002-Accepted-for-Presentation-at-the-92nd-EAS-2024-Congress-the-Annual-Meeting-of-the-European-Atherosclerosis.html?f=22&fvtc=4&fvtv=5976MediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis Society2024-03-20T23:00:00Z<![CDATA[LA JOLLA, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that two abstracts entitled “STUDY PROTOCOL TO EVALUATE MN-001’S (TIPELUKAST) EFFICACY, SAFETY AND TOLERABILITY IN SUBJECTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), HYPERTRIGLYCERIDEMIA (HTG) AND TYPE-2 DIABETES MELLITUS (T2DM)” and “MN-002, THE METABOLITE OF MN-001(TIPELUKAST) PROMOTES MACROPHAGE CHOLESTEROL EFFLUX” have been accepted and selected for poster presentation at the 92nd European Atherosclerosis Society (EAS) 2024 Congress to be held May 26-29, 2024.]]>https://www.globenewswire.com/news-release/2024/03/12/2844366/0/en/MediciNova-Announces-New-Data-and-Results-of-MN-166-ibudilast-in-Chlorine-Gas-induced-Acute-Lung-Injury-Presented-at-the-63rd-Annual-Meeting-of-the-Society-of-Toxicology.html?f=22&fvtc=4&fvtv=5976MediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of Toxicology2024-03-12T10:30:00Z<![CDATA[LA JOLLA, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova’s collaborator, Perenlei Enkhbaatar, MD, PhD, FAHA, Professor, Department of Anesthesiology, Director, Translational Intensive Care Unit, Charles Robert Allen Professor in Anesthesiology, University of Texas Medical Branch, presented new data and results of a nonclinical study evaluating MN-166 (ibudilast) in a chlorine gas-induced acute lung injury (CIALI) model at the Society of Toxicology (SOT) 63rd Annual Meeting and ToxExpo in Salt Lake City, Utah.]]>https://www.globenewswire.com/news-release/2024/01/17/2810539/0/en/MediciNova-Receives-a-Notice-of-Grant-for-a-New-Patent-Covering-MN-166-ibudilast-for-the-Treatment-of-Macular-Injury-in-China.html?f=22&fvtc=4&fvtv=5976MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China2024-01-17T11:00:00Z<![CDATA[LA JOLLA, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has received a Notice of Grant from the Chinese Patent Office for a new patent which covers MN-166 (ibudilast) for the treatment of macular injury associated with progressive multiple sclerosis.]]>https://www.globenewswire.com/news-release/2023/12/21/2800380/0/en/MediciNova-Announces-Abstract-Regarding-MN-166-ibudilast-in-Chlorine-Gas-induced-Lung-Injury-Accepted-for-Presentation-at-the-63rd-Annual-Meeting-of-the-Society-of-Toxicology.html?f=22&fvtc=4&fvtv=5976MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology2023-12-21T23:00:00Z<![CDATA[LA JOLLA, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding results of a nonclinical study of MN-166 (ibudilast) in chlorine gas-induced acute lung injury has been selected for a poster presentation at the Society of Toxicology (SOT) 63rd Annual Meeting and ToxExpo to be held March 10 - 14, 2024 in Salt Lake City, Utah. The poster will be presented by MediciNova’s collaborator, Perenlei Enkhbaatar, MD, PhD, FAHA, Professor, Department of Anesthesiology, Director, Translational Intensive Care Unit, Charles Robert Allen Professor in Anesthesiology at The University of Texas Medical Branch.]]>https://www.globenewswire.com/news-release/2023/12/06/2792155/0/en/MediciNova-Receives-a-Notice-of-Decision-to-Grant-for-a-New-Patent-Covering-MN-166-ibudilast-for-the-Treatment-of-Progressive-MS-in-Europe.html?f=22&fvtc=4&fvtv=5976MediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe2023-12-06T23:00:00Z<![CDATA[LA JOLLA, Calif., Dec. 06, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has received a Notice of Decision to Grant from the European Patent Office for a pending patent application which covers the combination of MN-166 (ibudilast) and interferon-beta for the treatment of progressive multiple sclerosis (progressive MS).]]>https://www.globenewswire.com/news-release/2023/11/19/2782852/0/en/MediciNova-Announces-New-Data-and-Results-of-a-Phase-2-Clinical-Trial-of-MN-166-ibudilast-in-Glioblastoma-Presented-at-the-28th-Annual-Meeting-of-the-Society-for-Neuro-Oncology.html?f=22&fvtc=4&fvtv=5976MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology2023-11-19T23:00:00Z<![CDATA[LA JOLLA, Calif., Nov. 19, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova’s collaborator, Justin Lathia PhD, Co-Director of the Brain Tumor Research and Therapeutic Development Center of Excellence at Cleveland Clinic Lerner Research Institute, and Professor, Department of Molecular Medicine at Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, and Patrick Wen, Director at the Center for Neuro-Oncology at Dana-Farber Cancer Institute, Professor of Neurology, Harvard Medical School, presented new data and results of a Phase 2 clinical trial of MN-166 (ibudilast) in glioblastoma (GBM) patients at the 28th Annual Meeting of the Society for Neuro-Oncology (SNO) held November 15 - 19, 2023 in Vancouver, Canada. The presentation also included data from preclinical studies which evaluated the combination of MN-166 (ibudilast) and anti-PD1 or anti-PD-L1 therapy in GBM models.]]>https://www.globenewswire.com/news-release/2023/10/27/2768137/0/en/MediciNova-s-Collaborator-Initiates-Clinical-Development-of-a-Gene-Therapy-Product-for-the-Treatment-of-Phenylketonuria.html?f=22&fvtc=4&fvtv=5976MediciNova’s Collaborator Initiates Clinical Development of a Gene Therapy Product for the Treatment of Phenylketonuria2023-10-27T05:00:00Z<![CDATA[LA JOLLA, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that its collaborator Genzyme Corporation, a subsidiary of Sanofi, has treated the first patient in a clinical trial of SAR444836 for the treatment of phenylketonuria (PKU). SAR444836 is a phenylalanine hydroxylase (PAH) replacement gene therapy product based on adeno-associated virus (AAV) vector technology which is covered under MediciNova’s assignment agreement with Genzyme Corporation.]]>https://www.globenewswire.com/news-release/2023/10/10/2757986/0/en/MediciNova-Receives-a-Notice-of-Allowance-for-a-New-Patent-Covering-the-Combination-of-MN-166-ibudilast-and-Riluzole-for-the-Treatment-of-Amyotrophic-Lateral-Sclerosis-ALS-in-Canad.html?f=22&fvtc=4&fvtv=5976MediciNova Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada2023-10-10T23:00:00Z<![CDATA[LA JOLLA, Calif., Oct. 10, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the Canadian Intellectual Property Office for a pending patent application which covers the combination of MN-166 (ibudilast) and riluzole for the treatment of amyotrophic lateral sclerosis (ALS).]]>https://www.globenewswire.com/news-release/2023/10/04/2755011/0/en/MediciNova-Receives-Gene-Therapy-Milestone-Payment.html?f=22&fvtc=4&fvtv=5976MediciNova Receives Gene Therapy Milestone Payment2023-10-04T23:00:00Z<![CDATA[LA JOLLA, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a milestone payment under MediciNova’s assignment agreement with Genzyme Corporation, a subsidiary of Sanofi. The milestone payment of $1 million is the result of the successful achievement of a clinical development milestone for a gene therapy product based on AAV (adeno-associated virus) vector technology that is covered under the assignment agreement.]]>